Therapeutic microbiota for the treatment and/or prevention of dysbiosis
AssigneesChildren's Medical Center Corporation, The Brigham and Women's Hospital, Inc.
InventorsTalal A. CHATILA, Azza ABDEL-GADIR, Emmanuel STEPHEN VICTOR, Rima RACHID, Lynn BRY, Georg GERBER
Life of this patent
Estimating the term…
Abstract
Disclosed are methods and compositions for the prevention and treatment of dysbiosis and associated conditions. In particular, described herein are microbial consortia, including monotherapies or minimal microbial consortia, that can prevent and/or cure dysbiosis and associated conditions. In certain embodiments, the therapy comprises Subdoligranulum variabile. In certain embodiments, the microbial consortia comprise certain members of the taxa Clostridiales, Bacteroidetes, Prevotella, and/or Parabacteroides.
Claims20
A method for the treatment or prevention of an atopic disease or disorder, the method comprising:
- administering to a subject in need thereof a pharmaceutical composition comprising a species of viable gut bacteria comprising a 16S rDNA sequence at least 97% identical to SEQ ID NO:
- 16, thereby treating, or preventing the atopic disease or disorder in the subject.
A method for reducing or eliminating a subject's immune reaction to an allergen, the method comprising:
- administering to a subject in need thereof a pharmaceutical composition comprising a species of viable gut bacteria comprising a 16S rDNA sequence at least 97% identical to SEQ ID NO:
- 16, thereby reducing or eliminating a subject's immune reaction to the allergen.
A method of reducing the number or activity of TH2 cells in a tissue of an individual in need thereof, the method comprising administering to the individual a pharmaceutical composition comprising a species of viable gut bacteria comprising a 16S rDNA sequence at least 97% identical to SEQ ID NO:
- 16, thereby reducing the number or activity of TH2 cells in a tissue of the individual.
Dependencies are inferred from the claim text.